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The target of rapamycin (TOR), a highly conserved
serine/threonine kinase, plays a central role in the con-
trol of eukaryotic cell growth. TOR exists in two func-
tionally and structurally distinct complexes, TOR com-
plex 1 (TORC1) and TOR complex 2 (TORC2). TORC1
controls cell growth via a rapamycin-sensitive signaling
branch regulating translation, transcription, nutrient
uptake, ribosome biogenesis, and autophagy. TORC2
controls the organization of the actin cytoskeleton
through a rapamycin-insensitive signaling branch and
in yeast consists of the six proteins AVO1, AVO2, AVO3,
BIT61, LST8, and TOR2. Here we have focused on the
characterization of TORC2. Our studies suggest that
TORC2 is oligomeric, likely a TORC2-TORC2 dimer.
AVO1 and AVO3 bind cooperatively to the N-terminal
HEAT repeat region in TOR2 and are required for
TORC2 integrity. AVO2 is a nonessential peripheral pro-
tein associated with AVO1 and AVO3. LST8 binds sepa-
rately to the C-terminal kinase domain region in TOR2
and appears to modulate both the integrity and kinase
activity of TORC2. TORC2 autophosphorylates sites in
AVO1 and AVO3, but TORC2 kinase activity is not re-
quired for TORC2 integrity. We have demonstrated that
mammalian TOR is also oligomeric. The architecture of
TORC2 is discussed in the context of TORC2 assembly
and regulation.
Target of rapamycin (TOR)1 is a highly conserved serine/
threonine kinase that controls cell growth in response to nu-
trients. TOR controls its various growth-related readouts via
two distinct signaling branches, a rapamycin-sensitive and a
rapamycin-insensitive branch (1, 2). The TOR protein consists
of several distinct domains. The N-terminal half of TOR com-
prises 20 tandemly repeated HEAT repeats (named for Hun-
tingtin, elongation factor 3, A subunit of protein phosphatase
2A and TOR1) (3). HEAT repeats mediate protein-protein in-
teractions and are required for localization of TOR to the
plasma membrane (4). The HEAT repeats are accompanied by
a so-called FAT domain that possibly serves as a scaffold or
protein interaction domain (5, 6). Following the FAT domain
are the FKBP-rapamycin binding domain, the kinase catalytic
domain, and a C-terminal FATC domain. Because TOR con-
tains a number of domains that may mediate protein-protein
interactions, TOR has been proposed to exist in a multiprotein
complex. Indeed, TOR is found in two complexes, TOR complex
1 (TORC1) and TOR complex 2 (TORC2), both of which are at
least partly conserved (7–12). These two complexes, which con-
tain both common and distinct proteins, account for the speci-
ficity of TOR signaling. TORC1 mediates the rapamycin-sensi-
tive signaling branch that positively regulates anabolic
processes such as translation and ribosome biogenesis and
negatively regulates catabolic processes such as RNA degrada-
tion, autophagy, and other degradative pathways (13–15).
TORC2 signaling is rapamycin-insensitive and is required for
the organization of the actin cytoskeleton. In Saccharomyces
cerevisiae, TORC2 signals to the actin cytoskeleton by activat-
ing the RHO1 GTPase switch (16, 17). Upon activation via the
exchange factor ROM2, RHO1 interacts with and activates
PKC1. Activated PKC1 subsequently regulates the organiza-
tion of the actin cytoskeleton by activating the mitogen-acti-
vated protein kinase cascade consisting of BCK1, MKK1/2, and
MPK1 (18). TORC2 also signals to the actin cytoskeleton via
the two recently described substrates SLM1 and SLM2 (19).
TORC1 in yeast consists of KOG1, TCO89, LST8, and either
TOR1 (TORC1-A) or TOR2 (TORC1-B). TORC2 is composed of
the proteins AVO1, AVO2, AVO3, LST8, TOR2, and the re-
cently described BIT61 (7, 20, 21). AVO1 is a 131-kDa (appar-
ent molecular mass 165 kDa) essential protein. Analysis of
avo1 mutant cells revealed that AVO1 acts positively in
TORC2. Similar to tor2 mutant cells, AVO1-depleted cells ex-
hibit a defect in polarization of the actin cytoskeleton. Further-
more, hyperactivation of the RHO1 GTPase or the PKC1-
mitogen-activated protein kinase pathway suppresses an avo1
mutation (7). AVO3, a conserved 164-kDa protein (known as
mAVO3 or rictor in mammals), is also essential and mediates
TOR signaling to the actin cytoskeleton in yeast and mammals
(11, 12). AVO3 (TSC11) was originally identified genetically as
a suppressor of a mutation in CSG2, a gene involved in sphin-
golipid biosynthesis, suggesting a link between sphingolipids
and TORC2 signaling in yeast (22). LST8, a highly conserved
and essential protein (known as mLST8 or GL in mammals),
is composed almost entirely of seven WD40 domains. As LST8
associates with both TORC1 and TORC2, lst8 mutant cells
resemble mutants defective in TORC1 or TORC2 (7, 23, 24).
AVO2 and BIT61 perform nonessential functions in TORC2 (7,
21). SLM1 and SLM2, the recently identified substrates of
TORC2, bind to TORC2 via AVO2, suggesting that AVO2
might serve as an adaptor protein (19).
The specific molecular functions of the individual proteins
within the two TOR complexes are largely unknown. We took a
biochemical approach to study the role of the different proteins
that form TORC2. We provide evidence that AVO1 and AVO3,
but not AVO2, act as scaffold proteins important for the integ-
rity of TORC2. LST8, which binds to the C-terminal half of
TOR2, appears to be involved in modulating both the integrity
of TORC2 and the kinase activity of TOR2.
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EXPERIMENTAL PROCEDURES
Strains, Plasmids, and Media—The S. cerevisiae strains and plas-
mids used are listed in Tables I and II, respectively. All strains are
isogenic derivatives of JK9–3da or TB50a. Rich media, YPD or YP-
Gal/Gly, and synthetic complete media, SD or SGal/Gly, were as
described previously (25, 26). Nitrogen starvation experiments were
performed with synthetic media as previously described (27). For
TOR2, AVO1, AVO3, and LST8 depletion experiments, cells from
logarithmically growing SGal/Gly or YPGal/Gly cultures were inocu-
lated into S.D. or YPD medium, respectively. Glucose cultures were
incubated with aeration for 15 h before cells were harvested for
analysis (7).
Genetic Techniques—Restriction enzyme digests and ligations were
performed according to standard methods. All enzymes and buffers
were obtained commercially (Roche Diagnostics). Escherichia coli
strains MH1 and DH5 were used for propagation and isolation of
plasmids. Yeast transformation was performed by the lithium acetate
procedure (28). PCR cassettes were used to generate gene deletions and
modifications as described (29, 30).
Gel Filtration—Yeast extracts from cells expressing HA-tagged
TOR2 were prepared as described below. Gel filtration was performed
using a Superose 6 HR 10/30 column (Amersham Biosciences) as pre-
viously described (7). Elution profiles of tagged TOR2 were analyzed by
immunoprecipitation/Western analysis and compared with the elution
profile of known standards.
Mammalian Tissue Culture, Transfections, Immunoprecipitation—
Human embryonic kidney 293 cells were maintained in Dulbecco’s
modified Eagle’s medium (Sigma) containing 10% fetal bovine serum.
Cells were transfected using jetPEI transfection reagent (Qbiogene)
following the manufacturer’s instructions and harvested after 24 h.
Lysate preparation and immunoprecipitation were performed as previ-
ously described (12).
Immunoprecipitations and TAP Pulldowns—A 200-ml culture was
grown in YPGal/Gly or YPD at 30 °C for 15 h to an A600 of 0.8, harvested
by centrifugation, and washed with ice-cold water. The pellet was
resuspended in 2 ml of lysis buffer (1 phosphate-buffered saline, 10%
glycerol, 0.5% Tween 20, plus inhibitors 10 mM NaF, 10 mM NaN3, 10
mM p-nitrophenylphosphate, 10 mM sodium pyrophosphate, 10 mM
-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, 1  Roche
complete inhibitor mixture). Cells were lysed by vortexing 5 30 s with
glass beads using a FastPrep machine (Savant Instruments). Extracts
were cleared with a 5-min, 2900  g spin. An aliquot of extract con-
taining 3 mg of protein was adjusted to 1 ml with lysis buffer plus
inhibitors. To immunoprecipitate an epitope-tagged protein, 1 l of
either concentrated 12CA5 (anti-HA) or 9E10 (anti-Myc) tissue culture
supernatant was added and the tubes were rotated for 1 h at 4 °C.
TABLE I
Strains
Strain Genotype
JK9–3da MATa leu2–3,112 ura3–52 trp1 his4 rme1 HMLa
JK9–3d MAT leu2–3,112 ura3–52 trp1 his4 rme1 HMLa
TB50a JK9–3da HIS4 his3
TB50 JK9–3d HIS4 his3
RL25–1c TB50a kanMX4-GAL1p-3HA-AVO1
RL39–1a TB50a AVO2–3HA-[kanMX4]
RL42–1c TB50a AVO3–3HA-[kanMX4]
RL58–1a TB50a LST8–3HA-[kanMX4]
RL59–2d TB50a LST8–13myc-[kanMX4]
RL69–1c TB50a AVO1–3HA-[kanMX4]
RL74 TB50a/ LST8–3HA-[kanMX4]/LST8–13myc-[kanMX4]
RL125a TB50a kanMX4-GAL1p-3HA-LST8
RS61–5b TB50a kanMX4-GAL1p-3HA-AVO3
SW62–7a TB50a HA-TOR2 AVO3–13myc-[kanMX4]
SW63–1d TB50 HA-TOR2 LST8–13myc-[kanMX4]
SW65–11c TB50a HIS3MX6-GAL1p-AVO3 AVO1–3HA-[kanMX4] AVO2–13myc-[kanMX4]
SW67–3b TB50 HIS3MX6-GAL1p-AVO3 AVO1–3HA-[kanMX4] LST8–13myc-[kanMX4]
SW68–3b TB50a HIS3MX6-GAL1p-AVO1 3HA-TOR2 AVO3–13myc-[kanMX4]
SW69–4d TB50a HIS3MX6-GAL1p-AVO1 LST8–3HA-[kanMX4] AVO2–13myc-[kanMX4]
SW70 TB50a 3HA-TOR2
SW72–5a TB50a HIS3MX6-GAL1p-AVO3 3HA-TOR2 AVO2–13myc-[kanMX4]
SW73–4b TB50a HIS3MX6-GAL1p-AVO1 AVO3–3HA-[kanMX4] AVO2–13myc-[kanMX4]
SW74–11b TB50a HIS3MX6-GAL1p-AVO1 LST8–3HA-[kanMX4] AVO3–13myc-[kanMX4]
SW75–10c TB50a HIS3MX6-GAL1p-AVO1 3HA-TOR2 LST8myc-[kanMX4]
SW76–5b TB50a HIS3MX6-GAL1p-AVO1 3HA-TOR2 AVO2–13myc-[kanMX4]
SW77–5d TB50a HIS3MX6-GAL1p-AVO3 3HA-TOR2 LST8–13myc-[kanMX4]
SW78–3a TB50a HIS3MX6-GAL1p-AVO3 LST8–3HA-[kanMX4] AVO2–13myc-[kanMX4]
SW80–1d TB50a HIS3MX6-GAL1p-TOR2 AVO2-TAP-[kanMX4]
SW84–1d TB50a HIS3MX6-GAL1p-AVO1 3HA-TOR2
SW94–1a TB50a HIS3MX6-GAL1p-TOR2 AVO3–13myc-[kanMX4]
SW100–1a TB50a HIS3MX6-GAL1p-LST8 3HA-TOR2
SW102–8b TB50a avo2::kanMX4 3HA-TOR2 AVO3–13myc-[kanMX4]
SW103–2d TB50 avo2::kanMX4 3HA-TOR2 LST8–13myc-[kanMX4]
SW104–3c TB50a kanMX4-GAL1p-LST8 3HA-TOR2 AVO3–13myc-[kanMX4]
SW105–3d TB50 HIS3MX6-GAL1p-TOR2 AVO1–3HA-[kanMX4] AVO3–13myc-[kanMX4]
SW106–5a TB50a HIS3MX6-GAL1p-TOR2 AVO1–3HA-[kanMX4] AVO2–13myc-[kanMX4]
SW107–8c TB50a HIS3MX6-GAL1p-TOR2 AVO3–3HA-[kanMX4] AVO2–13myc-[kanMX4]
SW108–4a TB50 kanMX4-GAL1p-LST8 3HA-TOR2 AVO2–13myc-[kanMX4]
SW109–3d TB50a HIS3MX6-GAL1p-AVO1 3HA-TOR2 LST8–13myc-[kanMX4] KOG1-TAP-[HIS3MX6]
SW110 TB50a/ AVO1–3HA-[kanMX4]/AVO1-TAP-[KlTRP1]
SW111 TB50a/ AVO2–3HA-[kanMX4]/AVO2–13myc-[kanMX4]
SW112 TB50a/ AVO3–3HA-[kanMX4]/AVO3–13myc-[kanMX4]
SW121–5c TB50a HIS3MX6-GAL1p-AVO3 2myc-TOR2 AVO1–3HA-[kanMX4]
SW123–1c TB50a HIS3MX6-GAL1p-3HA-TOR2
SW125 TB50a/ 3HA-TOR2 2myc-TOR2
SW126–1c TB50a 3HA-TOR2 KOG1-TAP-[HIS3MX6]
SW127–1a TB50a kanMX4-GAL1p-AVO3 3HA-TOR2 KOG1-TAP-[HIS3MX6]
SW128–5a TB50a HIS3MX6-GAL1p-AVO1 3HA-TOR2 KOG1-TAP-[HIS3MX6]
SW129–5c TB50a kanMX4-GAL1p-LST8 3HA-TOR2 KOG1-TAP-[HIS3MX6]
SW133 TB50a/ kanMX4-GAL1p-LST8/lst8::kanMX4 3HA-TOR2/2myc-TOR2
SW137–4b TB50a HIS3MX6-GAL1p-TOR2 tor1::kanMX4 LST8–13myc-[kanMX4]
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Afterward, 20 l of protein G-Sepharose slurry (Sigma) was added, and
the tubes were rotated for an additional 2 h at 4 °C. For TAP pulldowns,
20 l of IgG-Sepharose 6 fast flow (Amersham Biosciences) was added,
and tubes were rotated for 3 h at 4 °C. Beads were collected by centrif-
ugation, washed four times with 1 ml of lysis buffer, and resuspended in
2 SDS-PAGE sample buffer. For coimmunoprecipitations, the sample
was split in half and each aliquot was subjected to SDS-PAGE; one
aliquot was used for expression control and the other half to detect the
coimmunoprecipitated protein. After electrophoresis, the proteins were
electroblotted onto nitrocellulose, blocked in 5% milk in 1 phosphate-
buffered saline, 0.1% Tween 20, and incubated with primary antibody
(12CA5 or 9E10 1:10000 in blocking buffer or anti-Protein A 1:5000 in
blocking buffer) overnight at 4 °C. The membranes were washed and
incubated for 1 h at room temperature with the corresponding horse-
radish peroxidase-conjugated secondary antibody. The tagged proteins
were detected using ECL reagents (Amersham Biosciences).
Kinase Assays—Cells expressing HA-TOR2 in different mutant back-
grounds maintained on YPD or YPGal/Gly mediumwere inoculated into
YPGal/Gly liquid media and cultured overnight. Per strain (three as-
says), 3 liters of YPD was inoculated and grown at 30 °C for 15 h to an
A600 of 0.8 and then chilled on ice for 30 min. Cells were collected by
centrifugation, washed once in ice-cold water, and lysed with a Bead
Beater (Biospec Products) in 20 ml of lysis buffer (1 phosphate-
buffered saline, 10% glycerol, 0.5% Tween 20 plus inhibitors 10 mM
NaF, 10 mM NaN3, 10 mM p-nitrophenylphosphate, 10 mM sodium
pyrophosphate, 10 mM -glycerophosphate, 1 mM phenylmethylsulfonyl
fluoride, 1 Roche complete inhibitor mixture). The lysate was cleared
with a 5-min, 2900  g spin. Lysates were normalized to 20 ml and
250 mg of protein per strain (three kinase reactions) and passed over
250 l of Sepharose CL-4B (Sigma):Protein A-Sepharose (Amersham
Biosciences) (3:1) that had been previously equilibrated in lysis buffer.
To the flowthrough was added 150 l of anti-HA cross-linked to Protein
A-Sepharose beads. This mixture was rotated for 3 h at 4 °C, after
which the beads were collected in a column and washed with 30 ml of
lysis buffer. Antibody beads were split equally among three tubes. To
each aliquot, 1.5 g of 4E-BP1 (Stratagene) in 50 l of kinase buffer
(lysis buffer with 20% glycerol) and 6 l of 10 buffer (40 mM MnCl2,
100 mM dithiothreitol, 10 Roche complete inhibitor mixture-EDTA,
100 mM NaN3, 100 mM NaF, 100 mM p-nitrophenylphosphate, 100 mM
-glycerophosphate) were added. The kinase reaction was started with
the addition of 4 l of ATP mix (1.2 mM ATP, 2.5 Ci/l [-32P]ATP
(3000 Ci/mmol) in kinase buffer). Tubes were mixed (1200 rpm) at 30 °C
for 10 min. The reactions were terminated with the addition of 15 l of
5 SDS-PAGE sample buffer. Samples were subjected to SDS-PAGE
(5–20%). The top of the gel containing TOR2 was cut and subjected to
immunoblotting, while the lower part was Coomassie Blue stained.
Radioactivity was quantified using GeneSnap software (SynGene). Ki-
nase reactions using the kinase-dead version of TOR2 were performed
as described (19). The activity of immunopurified TORC2 was compared
with the activity of mock purified TORC2.
RESULTS
TORC2 Is an Oligomer—Gel filtration of yeast extracts re-
veals that TORC2 exists as two species, one of 1.5–2 MDa and
a second of 0.7–0.8 MDa (7) (Fig. 1A). The combined molecular
masses of TOR2 and its TORC2 partner proteins yield a mass
of 0.78 MDa. These findings suggest that TORC2 may exist in
a multimeric state. To determine whether the components of
TORC2 indeed interact with themselves, pairwise coimmuno-
precipitation experiments were performed with strains ex-
pressing heterologously tagged versions of TOR2, AVO1,
AVO2, AVO3, or LST8. As shown in Fig. 1B, each of the
examined components of TORC2 coimmunoprecipitated with
its differently tagged copy, suggesting that TORC2 exists in an
oligomeric state. Considering the molecular masses of the two
species observed by gel filtration, TORC2 most likely forms
a dimer.
Nutrient limitation does not affect the integrity of TORC2 as
measured by coimmunoprecipitation of different subunits (7).
FIG. 1. TORC2 is an oligomer. A, gel filtration elution profile of
TOR2. Clarified extracts prepared from cells expressing HA-TOR2
(SW70) were loaded onto a Superose 6 sizing column. 1-ml fractions
were collected, and HA-TOR2 was immunoprecipitated and visualized
by immunoblotting. The elution patterns of known molecular mass
standards are indicated. B, components of TORC2 interact with them-
selves. Lysates from cells expressing HA-TOR2 and Myc-TOR2
(SW125), AVO1-HA and AVO1-TAP (SW110), AVO2-HA and AVO2-
Myc (SW111), AVO3-HA and AVO3-Myc (SW112), or LST8-HA and
LST8-Myc (RL74) were subjected to immunoprecipitation with anti-
Myc or pull down with IgG-Sepharose and probed with anti-HA to test
for coimmunoprecipitation (coIP). Expression of HA-tagged proteins
(expression 1) and Myc- or TAP-tagged proteins (expression 2) are
shown. As a negative control (neg), lysates from cells expressing HA-
TOR2 (SW70), AVO1-HA (RL69–1c), AVO2-HA (RL39–1a), AVO3-HA
(RL42–1c), or LST8-HA (RL58–1a) were subjected to immunoprecipi-
tation with anti-Myc or pull down with IgG-Sepharose and probed with
anti-HA. C, mTOR interacts with itself. Human embryonic kidney 293
cells were cotransfected with plasmids expressing HA-mTOR and Myc-
mTOR. Protein extracts were prepared, and Myc-mTOR was immuno-
precipitated with anti-Myc antibody and probed with anti-HA to test for
coimmunoprecipitation of HA-mTOR (coIP). Expression of HA- (HA-
mTOR) and Myc-tagged (Myc-mTOR) mTOR are shown. As a negative
control (neg), lysates from human embryonic kidney 293 cells trans-
fected with empty vector and pHA-mTOR were subjected to immuno-
precipitation with anti-Myc and probed with anti-HA.
TABLE II
Plasmids
Plasmids Description
pHA-TOR2 Expresses HA-tagged TOR2 from TOR2 promoter; pRS314::3HA-TOR2 (CEN, TRP1) (35)
pHA-TOR2-KD Expresses HA-tagged TOR2 kinase-dead from TOR2 promoter; pRS314::3HA-TOR2D2298E
(CEN, TRP1) (35)
pSW62 Expresses HA-tagged TOR2-(1290–2474) from TOR2 promoter. Cloned as 4.1-kb SacI-
PstI fragment into YEplac195::TOR2 promoter ATG-3HA (2, URA3)
pSW67 Expresses HA-tagged TOR2-(1–1390) from TOR2 promoter. Cloned as 4.7-kb BamHI-
PstI fragment into YEplac195::3HA CYC1 terminator (2, URA3)
pSW75 Expresses HA-tagged LST8 from LST8 promoter. Cloned as 1.7-kb SacI-PstI fragment
into YCplac111::3HA CYC1 terminator (CEN, LEU2)
pAN54 Expresses Myc-tagged TOR2 from TOR2 promoter; YCplac111::2myc-TOR2 (CEN, LEU2)
pHA-mTOR Expresses HA-tagged mTOR from the CMV promoter (36)
pmyc-mTOR Expresses Myc-tagged mTOR from the CMV promoter (8)
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However, this assay would not detect whether TORC2 is reg-
ulated by association of TORC2 monomers, as different sub-
units would remain associated within a monomer. To investi-
gate a possible role of TORC2-TORC2 oligomerization in
TORC2 regulation, we examined whether heterologously
tagged TOR2 or LST8 coimmunoprecipitated in cells that were
starved for nitrogen (60 min). The interaction of Myc-TOR2
with HA-TOR2 or of LST8-Myc with LST8-HA was unaffected
by nitrogen starvation (data not shown). Likewise, the molec-
ular mass of TORC2 as determined by gel filtration was not
affected by nutrient conditions (data not shown). Thus, TORC2
appears to exist in a dimeric or higher order state that is
unaffected by nutrient limitation. However, the signaling cues
that regulate TORC2 are unknown. Although ample evidence
has been presented that TORC1 is regulated by nutrient cues,
TORC2 is only assumed to be regulated in response to nutrient
conditions. The significance of TORC2 oligomerization remains
to be determined.
To investigate whether mammalian TOR (mTOR) also oli-
gomerizes, we examined whether Myc-mTOR coimmunopre-
cipitates with HA-mTOR in an extract prepared from human
embryonic kidney 293 cells coexpressing the two differently
tagged versions of mTOR. Myc- and HA-mTOR efficiently co-
immunoprecipitated, indicating that, similar to TOR2 in yeast,
mTOR oligomerizes in mammalian cells (Fig. 1C). It remains to
be determined whether mTOR oligomerizes in mTORC1,
mTORC2, or both. Pretreatment of cells with rapamycin (200
nM, 30 min) did not affect the mTOR-mTOR interaction (data
not shown).
AVO1 and AVO3 Are Important for the Structural Integrity of
TORC2—To study the contribution of TORC2 components to
TORC2 architecture, we depleted cells of individual TORC2
components and assayed, by coimmunoprecipitation, the inter-
actions of the remaining subunits. Because most components of
TORC2 are essential, we conditionally depleted cells of an
essential partner by placing the corresponding gene under the
control of the GAL1 promoter, which is active in galactose- and
inactive in glucose-containing media. After growing cells in
glucose medium for 15 h, the protein under control of the GAL1
promoter was no longer detectable by immunoblotting (data
not shown). Cells depleted for a protein are referred to as
mutant cells. The expression levels of the analyzed, remaining
proteins did not vary upon depletion of any single TORC2
component.
To investigate the role of AVO1 in the architecture of
TORC2, interactions between the remaining TORC2 proteins
were analyzed in an avo1 mutant. As shown in Fig. 2, upon
depletion of AVO1, AVO2 and AVO3 no longer interacted with
TOR2 (Fig. 2, A and B), LST8 (Fig. 2, C and D), or with each
other (Fig. 2E). Conversely, TOR2 and LST8 still interacted in
the absence of AVO1 (Fig. 2F). Because TOR2 and LST8 are
also components of TORC1-B, coimmunoprecipitation of these
two proteins could reflect an interaction within TORC1-B and
could thus be misleading. To determine whether the interac-
tion between TOR2 and LST8 in avo1 cells was due to contam-
ination by TORC1-B, cell extracts were depleted of TORC1 by
precipitating the TORC1-specific component KOG1. TAP-
tagged KOG1 was precipitated by incubating the cell extracts
with IgG-Sepharose prior to the coimmunoprecipitation exper-
iment. When TORC1 was depleted, TOR2 still associated with
LST8 in the absence of AVO1 (data not shown), indicating that
this interaction was indeed TORC1-B-independent. Further-
more, TOR2 was found primarily in TORC2 (7) (data not
shown). Thus, AVO1 is required for the binding of AVO2 and
AVO3 to TOR2, LST8, and to each other but is not required for
the interaction between TOR2 and LST8.
Cells depleted of AVO3 showed similar defects in TORC2
integrity as described above. In avo3 mutant cells, AVO1 and
AVO2 no longer associated with TOR2 (Fig. 3, A and B), LST8
(Fig. 3, C and D), or with each other (Fig. 3E). TOR2 still
interacted with LST8 in the absence of AVO3 (Fig. 3F). The
above observations combined with the fact that AVO2 is non-
essential suggest that AVO2 is a peripheral protein that binds
TOR2 via AVO1 and AVO3, although we cannot exclude the
possibility that AVO1 and AVO3 cause a conformational
change in TOR2 that allows AVO2 to bind directly to TOR2.
Consistent with these models, AVO3 still interacted with TOR2
in an avo2mutant (Fig. 4A). Furthermore, deletion of AVO2 did
FIG. 2. AVO1 is important for the structural integrity of
TORC2. Lysates from cells expressing GAL1p-AVO1 (AVO1 under
control of the galactose promoter) and HA- or Myc-tagged versions of
two TORC2 components were subjected to immunoprecipitations with
anti-HA or anti-Myc. Cells expressing AVO1 (AVO1) (cells grown in
galactose medium) were compared with AVO1-depleted cells (avo1)
(cells grown for 15 h in glucose medium). Immunoprecipitates were
probed with anti-Myc or anti-HA to detect a coimmunoprecipitated
partner protein (coIP, top panel). The expression levels of the HA- or
Myc-tagged TORC2 components (expression) are shown in the middle
and bottom panels. GAL1pAVO1 HA-TOR2 AVO2-myc (SW76–5b) (A),
GAL1pAVO1 HA-TOR2 AVO3-myc (SW68–3b) (B), GAL1pAVO1
LST8-HA AVO2-myc (SW69–4d) (C), GAL1pAVO1 LST8-HA AVO3-
myc (SW74–11b) (D), GAL1pAVO1 AVO3-HA AVO2-myc (SW73–4b)
(E), GAL1pAVO1 HA-TOR2 LST8-myc (SW75–10c) (F).
FIG. 3. AVO3 is important for the structural integrity of
TORC2. Lysates from cells expressing GAL1p-AVO3 (AVO3 under
control of the galactose promoter) and HA- or Myc-tagged versions of
two TORC2 components were subjected to immunoprecipitations with
anti-HA or anti-Myc. Cells expressing AVO3 (AVO3) (cells grown in
galactose medium) were compared with AVO3-depleted cells (avo3)
(cells grown for 15 h in glucose medium). Immunoprecipitates were
probed with anti-Myc or anti-HA to detect a coimmunoprecipitated
partner protein (coIP, top panel). The expression levels of the HA- or
Myc-tagged TORC2 components (expression) are shown in the middle
and bottom panels. GAL1pAVO3 AVO1-HA myc-TOR2 (SW121–5c) (A),
GAL1pAVO3 HA-TOR2 AVO2-myc (SW72–5a) (B), GAL1pAVO3
AVO1-HA LST8-myc (SW67–3b) (C),GAL1pAVO3 LST8-HA AVO2-myc
(SW78–3a) (D), GAL1pAVO3 AVO1-HA AVO2-myc (SW65–11c) (E),
GAL1pAVO3 HA-TOR2 LST8-myc (SW77–5d) (F).
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not affect the interaction between TOR2 and LST8 (Fig. 4B).
Removal of LST8 destabilized but did not abolish the TOR2-
AVO3 or the TOR2-AVO2 interaction (Fig. 4, C and D). Thus,
AVO1 and AVO3 bind TOR2 cooperatively and are particularly
important for the integrity of TORC2.
To investigate whether AVO1, AVO2, and AVO3 form a
complex independent of TOR2, pairwise interactions between
AVO1, AVO2, and AVO3 were examined in TOR2-depleted
cells. As shown in Fig. 4, E–G, AVO1-AVO3 was significantly
destabilized and the AVO1-AVO2 and AVO2-AVO3 interac-
tions were abolished in TOR2-depleted cells. Thus, AVO1,
AVO2, and AVO3 fail to form a complex in the absence of
TOR2. In summary, AVO1, AVO3, and TOR2 are interdepen-
dent members of a TORC2 core complex. LST8 binds TOR2
independently of AVO1, AVO2, and AVO3. AVO2 is likely a
peripheral protein associated with AVO1 and AVO3.
LST8 Binds to the C-terminal Kinase Domain Region in
TOR2, and AVO3 Associates with the N-terminal HEAT Repeat
Region in TOR2—To identify the regions in TOR2 that interact
with AVO1, AVO3, and LST8, coimmunoprecipitation experi-
ments were performed with plasmid-encoded deletion variants
of TOR2. HA-tagged deletion variants of TOR2 were expressed
in strains containing Myc-tagged partner proteins. LST8 inter-
acted with the C-terminal half of TOR2 containing the FAT,
FKBP-rapamycin binding, kinase, and FATC domains, but not
with the N-terminal half of TOR2 containing the HEAT repeats
(Fig. 5A). The binding of AVO1 and AVO3 to TOR2 appeared to
be more complex as we failed to detect an interaction of these
two proteins with either the N-terminal or the C-terminal half
of TOR2. Because this could be due to interference by chromo-
somally encoded wild-type TOR2, wild-type TOR2 was depleted
using a strain that contained chromosomal TOR2 under the
control of the GAL1 promoter. In cells grown in glucose me-
dium, we observed a weak interaction between AVO3 and the
N-terminal half of TOR2 consisting of the HEAT repeats, but
not between AVO3 and the C-terminal half of TOR2 (Fig. 5B).
Using this approach, we did not detect an interaction between
AVO1 and either of the TOR2 deletion variants (data not
shown). AVO1 might bind, via multiple contacts, to various
domains in TOR2. In summary, AVO3 seems to associate with
the HEAT repeats of TOR2, whereas LST8 avidly binds the
C-terminal half of TOR2.
FIG. 4.Role of AVO2, LST8, and TOR2 in the integrity of TORC2. A and B, AVO2 is not required for AVO3 and LST8 to interact with TOR2.
Lysates from wild-type (AVO2) or avo2 mutant cells (avo2) expressing HA- or Myc-tagged versions of two TORC2 components were subjected to
immunoprecipitations with anti-HA or anti-Myc. Immunoprecipitates were probed with anti-HA to detect a coimmunoprecipitated partner protein
(coIP, top panel). The expression levels of the HA- or Myc-tagged TORC2 components (expression) are shown in the middle and bottom panels. C
and D, depletion of LST8 destabilizes the interaction between AVO3 and AVO2 with TOR2. Lysates from cells expressing GAL1p-LST8 (LST8
under control of the galactose promoter) and HA- or Myc-tagged versions of two TORC2 components were subjected to immunoprecipitations with
anti-HA or anti-Myc. Cells expressing LST8 (LST8) (cells grown in galactose medium) were compared with LST8-depleted cells (lst8) (cells grown
for 15 h in glucose medium). Immunoprecipitates were probed with anti-Myc to detect a coimmunoprecipitated partner protein (coIP, top panel).
The expression levels of the HA- or Myc-tagged TORC2 components (expression) are shown in themiddle and bottom panels. E–G, TOR2 is required
for the interaction between AVO1, AVO2, and AVO3. Lysates from cells expressing GAL1p-TOR2 (TOR2 under control of the galactose promoter)
and HA- or Myc-tagged versions of two TORC2 components were subjected to immunoprecipitations with anti-HA or anti-Myc. Cells expressing
TOR2 (TOR2) (cells grown in galactose medium) were compared with TOR2-depleted cells (tor2) (cells grown for 15 h in glucose medium).
Immunoprecipitates were probed with anti-Myc to detect a coimmunoprecipitated partner protein (coIP, top panel). The expression levels of the
HA- or Myc-tagged TORC2 components (expression) are shown in themiddle and bottom panels. HA-TOR2 AVO3-myc (SW62–7a), avo2 HA-TOR2
AVO3-myc (SW102–8b) (A), HA-TOR2 LST8-myc (SW63–1d), avo2 HA-TOR2 LST8-myc (SW103–2d) (B), GAL1pLST8 HA-TOR2 AVO3-myc
(SW104–3c) (C), GAL1pLST8 HA-TOR2 AVO2-myc (SW108–4a) (D), GAL1pTOR2 AVO1-HA AVO3-myc (SW105–3d) (E), GAL1pTOR2 AVO1-HA
AVO2-myc (SW106–5a) (F), GAL1pTOR2 AVO3-HA AVO2-myc (SW107–8c) (G).
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LST8, but Not AVO1 or AVO3, Is Required for TOR2 Kinase
Activity—To investigate the contribution of AVO1, AVO3, and
LST8 to TORC2 kinase activity, the activity of immunopurified
TORC2 lacking AVO1, AVO3, or LST8 was determined in an in
vitro kinase assay using 4E-BP1 as a substrate (see “Experi-
mental Procedures”). 4E-BP1, a physiological substrate for
mTORC1, is unstructured and a nonphysiological substrate for
a number of unrelated kinases, including TORC2 (19). The
activity of TOR2 toward 4E-BP1 was determined by performing
kinase reactions with immunopurified TOR2. The phosphoryl-
ation was normalized to the amount of TOR2 present in the
kinase reaction as determined by immunoblotting. In wild-type
and AVO1-, AVO3-, or LST8-depleted cells, the rate of 4E-BP1
phosphorylation was linear up to 30 min of incubation time
(data not shown). Kinase activity of TOR2 immunopurified
from avo1 or avo3 mutant cells was not significantly altered
compared with TOR2 purified from wild-type cells (Fig. 6).
However, TOR2 isolated from LST8-depleted cells exhibited
50% less kinase activity compared with TOR2 purified from
wild-type cells. To exclude possible contamination by
TORC1-B, which could also be present in the TOR2 immuno-
precipitate, extracts were depleted of TORC1 as described
above, prior to immunopurification of TOR2. Depletion of
TORC1 did not significantly alter the results (data not shown),
indicating that the TOR2-associated kinase activity was pri-
marily, if not exclusively, TORC2 mediated. TOR2 is primarily
associated with TORC2 (7).
Because AVO1 or AVO3 depletion, which results in the dis-
ruption of TORC2 integrity, did not change TOR2-mediated
phosphorylation of 4E-BP1, we conclude that AVO1 and AVO3
are not required for intrinsic TORC2 catalytic activity. In con-
trast, LST8 depletion caused a decrease in 4E-BP1 phospho-
rylation, suggesting that LST8 may modulate TOR2 kinase
activity. These effects on kinase activity are consistent with the
above findings that LST8 binds TOR2 in or around the C-
terminal kinase domain, whereas AVO1 and AVO3 bind the
N-terminal region of TOR2.
TORC2 Autophosphorylates Sites in AVO1 and AVO3—
AVO1 and AVO3 are phosphorylated during an in vitro kinase
assay with purified TORC2 (Fig. 7). To determine whether this
is autophosphorylation by TORC2 or phosphorylation by a con-
taminating kinase, an in vitro kinase assay was performed
with TORC2 containing a kinase-dead version of TOR2 (TOR2-
KD). Kinase-dead TORC2 was isolated from cells after turning
off expression of the endogenous wild-type copy of TOR2 as
described previously (19). Kinase-dead TORC2 failed to phos-
phorylate AVO1 and AVO3 (Fig. 7), suggesting that TORC2
autophosphorylates sites in AVO1 and AVO3. Mass spectro-
FIG. 6. LST8, but not AVO1 or AVO3, is required for TOR2
kinase activity.Wild-type cells expressing HA-TOR2 (SW70) and cells
expressing GAL1pAVO1 (SW84–1d), GAL1pAVO3 (SW72–5a), or
GAL1pLST8 (SW100–1a) and HA-TOR2 were grown in glucose me-
dium for 15 h. HA-TOR2 was immunoprecipitated from lysates of wild-
type cells (WT) or AVO1 (avo1)-, AVO3 (avo3)-, or LST8 (lst8)-depleted
cells and tested for 4E-BP1 kinase activity. The autoradiograph shows
4E-BP1 phosphorylation (4E-BP1 32P). Coomassie Blue-stained total
4E-BP1 protein and the immunoblot of total HA-tagged TOR2 protein
are also depicted. 4E-BP1 phosphorylation was normalized to the
amount of TOR2 added to the respective kinase assay and graphed.
Kinase reactions were performed in triplicate; one of three independent
experiments is shown.
FIG. 7. TORC2 autophosphorylates sites in AVO1 and AVO3.
Cells expressing GAL1pTOR2 and TAP-tagged AVO2 (SW80–1d) were
transformed with empty vector (mock) or plasmids expressing HA-
tagged TOR2 (TOR2, pHA-TOR2), or HA-tagged kinase-dead TOR2
(TOR2-KD, pHA-TOR2-KD). Cells were grown for 15 h in glucose me-
dium (to repress expression of genomic TOR2). TORC2 was isolated via
TAP-tagged AVO2 using IgG-Sepharose beads and subjected to in vitro
kinase assays. The autoradiograph shows AVO1 and AVO3 phospho-
rylation (AVO1 32P and AVO3 32P). Total HA-tagged TOR2/TOR2-KD
protein visualized by immunoblotting is also depicted.
FIG. 5. AVO3 and LST8 bind the N- and C-terminal regions of TOR2, respectively. A, LST8 binds to the C-terminal kinase domain region
in TOR2. Cells expressing Myc-tagged LST8 (RL59–2d) were transformed with empty vector () or plasmids expressing HA-tagged TOR2 (TOR2,
pHA-TOR2), the N-terminal half of HA-tagged TOR2 (TOR2-(1–1390), pSW67), or the C-terminal half of HA-tagged TOR2 (TOR2-(1290–2474),
pSW62). Protein lysates were prepared and immunoprecipitated with anti-HA. Immunoprecipitates were probed with anti-Myc to detect
coimmunoprecipitated LST8 (coIP, top panel). The expression levels of LST8 and TOR2 variants (expression) are shown in the middle and bottom
panels. B, AVO3 associates with the N-terminal HEAT repeat region in TOR2. Cells expressing GAL1p-TOR2 (TOR2 under control of the galactose
promoter) and Myc-tagged AVO3 (SW94–1a) were transformed with empty vector () or plasmids expressing HA-tagged TOR2 (TOR2, pHA-
TOR2), the N-terminal half of HA-tagged TOR2 (TOR2-(1–1390), pSW67), or the C-terminal half of HA-tagged TOR2 (TOR2-(1290–2474), pSW62).
Cells were grown for 15 h in glucose medium (to repress expression of genomic TOR2). Protein lysates were prepared and immunoprecipitated with
anti-HA. Immunoprecipitates were probed with anti-Myc to detect coimmunoprecipitated AVO3 (coIP, top panel). The expression levels of AVO3
and TOR2 variants (expression) are shown in the middle and bottom panels.
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metric analysis of isolated TORC2 indicates that AVO1 and
AVO3 are also phosphorylated in vivo on many sites.2 The
significance of AVO1 and AVO3 phosphorylation remains to be
determined. AVO1 and AVO3 phosphorylation could be impor-
tant for the regulation of TORC2 kinase activity or for mediat-
ing signaling to downstream effectors. Interestingly, isolations
of wild-type and kinase-dead TORC2 routinely yielded similar
amounts of the two complexes (Fig. 7), suggesting that the
kinase activity of TOR2 is not required for TORC2 integrity.
DISCUSSION
We have analyzed the molecular interactions and functions
of the proteins within TORC2. A model summarizing our find-
ings on the molecular organization of TORC2 is shown in Fig.
8. The protein-protein interactions in TORC2 appear to be
complex. The assembly of a given protein into TORC2 may
involve binding to multiple partner proteins through various
domains. This may account for the observation that directed
two-hybrid binding assays failed to detect an interaction be-
tween any two components of TORC2 other than between
AVO1 and the N-terminal region of AVO3 (data not shown).
Furthermore, upon depletion of AVO1, AVO3, or TOR2, the
interactions of the remaining two proteins with each other in
any combination or with the nonessential peripheral protein
AVO2 were abolished or significantly destabilized. AVO1 and
AVO3 may bind cooperatively to the N-terminal HEAT repeat
region of TOR2 to form a core complex that then associates with
AVO2 and possibly BIT61. AVO1 and AVO3 thus perform a
scaffold-like function. Although in our model we show that both
AVO1 and AVO3 bind directly to TOR2, we cannot firmly
conclude that their cooperative binding to TOR2 involves direct
contacts between TOR2 and both AVO1 and AVO3. AVO2 may
act as an adaptor protein for TORC2 substrates such as SLM1
and SLM2 (19). Our model suggests that the rapamycin resist-
ance of TORC2 could be due to AVO1 masking the FKBP-
rapamycin binding site in TOR2. This is based on the observa-
tions that AVO1, unlike AVO3, is unable to bind an isolated
N-terminal fragment of TOR2 and that LST8 does not prevent
FKBP-rapamycin binding in TORC1. LST8 binds to the C-
terminal kinase domain region of TOR2 independently of
AVO1, AVO2, and AVO3 and unlike the AVOs is required for
the intrinsic kinase activity of TOR2. Our model on the orga-
nization of TORC2 is consistent with previous studies on
TOR1-TOR2 and TOR2-TOR1 hybrids suggesting that TOR1
and TOR2 are functionally different based on their amino
terminus (31).
LST8 is a subunit of both TORC1 and TORC2 and acts
positively with TOR in each complex (7, 20, 32), suggesting that
LST8 may perform a similar function(s) in TORC1 and TORC2.
Our data suggest that LST8 bound to the C-terminal kinase
domain region of TOR2 is required for intrinsic TOR2 kinase
activity and for stability of TORC2. This is consistent with the
function of mLST8 (mammalian ortholog of LST8; also known
as GL) in mammalian cells (7, 10). mLST8 binds to the kinase
domain region of mTOR, and overexpression of mLST8 stimu-
lates mTOR kinase activity, underscoring a conserved role for
LST8 in modulation of TOR kinase activity (10). Furthermore,
mLST8 stabilizes the interaction between mTOR and raptor in
mTORC1 (10). LST8 was originally identified in a synthetic
lethal screen with sec13 and was shown to be required for
transport of the general amino acid permease GAP1 from Golgi
to the plasma membrane (23). However, the effect of LST8 on
GAP1 sorting appears to be an indirect consequence of LST8
acting in the TOR signaling pathway (26, 32, 33). Furthermore,
TOR1 is still associated with internal membranes in a lst8
mutant, indicating that LST8 is not required for localization of
at least TOR1 to membranes (32).
We have shown that TORC2 is oligomeric, most likely a
TORC2-TORC2 dimer. The oligomerization of TORC2 accounts
for the high molecular mass (1.5–2 MDa) of the complex. Oli-
gomerization of TORC2 likely occurs via at least TOR2 because
the self-association of LST8 (i.e. LST8-LST8) is disrupted in
cells depleted for TOR2, and TOR2 still self-associates in
AVO3- or LST8-depleted cells.3 ATM, like TOR amember of the
phosphatidylinositol kinase-related protein kinase family, is
regulated by dimerization (34). By analogy, oligomerization of
TORC2, and possibly TORC1, could also be an important mech-
anism for the regulation of TOR activity. Consistent with this
notion, we find that only the high molecular mass, oligomeric
form of TORC2 (Fig. 1A) exhibits kinase activity as assayed by
4E-BP1 phosphorylation.3 However, until the upstream cues
that regulate TORC2 are defined, the role of oligomerization in
TORC2 regulation remains to be determined. The role of oli-
gomerization may be conserved as mTOR is also oligomeric. We
anticipate that the overall molecular organization of TORC2
is conserved.
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